Cerebrovascular disease is a major contributor to cardiovascular morbidity and mortality in the well-treated HIV population. However, we have little understanding of stroke with regard to etiology, risk, progression, and treatment in HIV. Rather, more abundant data are available among persons living with HIV (PLWHIV) on other critical types of cardiovascular disease (CVD), such as myocardial infarction and heart failure [1,2].

With the advent of contemporary antiretroviral (ART) regimens, many HIV-related stroke risk factors including uncontrolled viremia, immunosuppression, as well as ART-induced dyslipidemia, have been significantly reduced. Moreover, well-treated PLWHIV may be older and thus predisposed to other potentiators of stroke typically acquired with age. In addition, chronic inflammation and immune activation are underlying non-traditional mediators of metabolic disease in HIV, which may have an important role in the pathogenesis of stroke.

Prior studies have demonstrated an increased relative risk of stroke among PLWHIV [3], and to date most studies have been primarily observational [4]. Utilizing a large healthcare database, Alonso et al. recently demonstrated the rate of incident stroke was almost three times higher among PLWHIV compared to uninfected individuals who were age and sex matched [5]. The majority of prior analyses could not differentiate between relevant clinical subtypes of stroke—hemorrhagic vs. ischemic, as in the current study.

In this issue of EClinicalMedicine, Hatleberg et al. take advantage of the D:A:D cohort to uniquely discern relevant risk factors, including traditional and HIV-related, that are predictors of cerebrovascular subtypes among PLWHIV [6]. The D:A:D study has provided landmark evidence linking ART and CVD [7] and now informs us further about stroke subtypes among PLWHIV, adding new information to the field. The data show that traditional stroke risk factors, such as hypertension and age, were predictors of both stroke subtypes. Male sex, prior CVD, and tobacco use conferred an increased risk of ischemic stroke, while HCV and kidney disease conferred an increased risk of hemorrhagic stroke.

Participants were assigned a diagnosis of either ischemic or hemorrhagic stroke based on a validated algorithm. A large number of strokes could not be classified which may have affected the analyses. In addition, the diagnosis of hypertensive disorder was based on a single blood pressure measurement, which could have led to overdiagnoses of hypertension. Other critical known stroke-related risk factors, such as atrial fibrillation and history of cardiomyopathy, and other non-traditional HIV-related risk factors, including generalized inflammation and inflammatory-induced endothelial dysfunction, could not be investigated. Even deeper stratification of ischemic stroke into large or small vessel disease or thromboembolic disease could have been performed, but was outside the scope of this study.

Animal models which mimic HIV infection show that the virus impacts ischemic stroke by directly affecting the blood brain barrier integrity, contributing to small vessel disease and heightening the inflammatory response [8]. The CNS is home to viral reservoirs, so this is still a relevant mechanism to those well-treated PLWHIV [9]. In addition, ART that penetrate the CNS may dampen injury and hasten post-stroke recovery [8]. Those on ART with limited penetration of the CNS may be a subgroup at higher risk for stroke, which needs to be formally investigated.

The authors conclude many predictors were otherwise traditional risk factors associated with stroke and do not necessarily warrant generation of a specific risk prediction score in HIV. This remains to be seen as we could hypothesize other relevant factors such as inflammation were not adequately studied and that each of these more traditional risk factors could be weighted differently when compared to the uninfected population. Moreover, many of the risk factors highlighted by this study could be inflammatory-driven (hypertension, CVD, HCV, kidney disease). While stroke prediction in HIV has not been specifically assessed utilizing the ASCVD calculator, we know the ASCVD risk algorithm as a composite calculator may be suboptimal and underestimate CVD risk among PLWHIV [10]. Further characterization of risk factors may help strengthen risk algorithms originally designed for use in the general population to be harnessed as a primary prevention tool with the goal of reducing overall stroke incidence in HIV.

The REPRIEVE trial will test for the first time the effects of statins on composite MACE events, inclusive of nonfatal stroke or transient ischemic attack. If hypertension is a strong risk factor for stroke in HIV, future guidelines may evolve to optimize preferred antihypertensive agents.
Data are available to suggest increased aldosterone may be present in
the HIV population [11]. As excess aldosterone has important implica-
tions for hypertension, targeting aldosterone blockade with classes of
medications, such as ACE inhibitors, ARBs, and mineralocorticoid antag-
onists may be clinically useful in HIV to reduce stroke risk.

Disclosure Summary

SS has been supported by an educational grant from Gilead Sciences
and Merck to participate in a CME activity and has received research
funding from Gilead Sciences; SKG has received research funding from
Gilead Sciences, KOWA, and Theratechnologies and has served as a con-
sultant for Theratechnologies; all disclosures from all authors are unre-
related to this manuscript.

References

[1] Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction
rates and cardiovascular risk factors among patients with human immunodeficiency
virus disease. J Clin Endocrinol Metab 2007;92(7):2506–12.

[2] Freiberg MS, Chang CH, Skanderson M, et al. Association between HIV infection and
the risk of heart failure with reduced ejection fraction and preserved ejection
fraction in the antiretroviral therapy era: results from the veterans aging cohort
study. JAMA Cardiol 2017;2(5):536–46.

[3] Chow FC, Regan S, Feske S, Meigs JB, Grinspoon SK, Triant VA. Comparison of ische-
mic stroke incidence in HIV-infected and non-HIV-infected patients in a US health
care system. J Acquir Immune Defic Syndr 2012;60(4):351–8.

[4] Bogorodskaya M, Chow FC, Triant VA. Stroke in HIV. Can J Cardiol 2019;35(3):280–7.

[5] Alonso A, Barnes AE, Guest JL, Shah A, Shao IY, Marconi V. HIV infection and inci-
dence of cardiovascular diseases: an analysis of a large healthcare database. J Am
Heart Assoc 2019;8(14):e012241.

[6] Hatleberg CI, Ryom L, Kamara D, et al. Predictors of ischemic and hemorrhagic
strokes among people living with HIV: the D:A:D international prospective
multicohort study. EClinicalMedicine 2019;13:91–100.

[7] Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV pa-
tients—association with antiretroviral therapy. Results from the DAD study. AIDS
2003;17(8):1179–93.

[8] Bertrand L, Meroth F, Tournebize M, Leda AR, Sun E, Toborek M. Targeting the HIV-
infected brain to improve ischemic stroke outcome. Nat Commun 2019;10(1):2009.

[9] Joseph SB, Kinzer LP, Bowman NM, et al. HIV-1 RNA detected in the CNS after years
of suppressive antiretroviral therapy can originate from a replicating CNS reservoir
or clonally expanded cells. Clin Infect Dis 2018 [Epub ahead of print].

[10] Triant VA, Perez J, Regan S, et al. Cardiovascular risk prediction functions underesti-
mate risk in HIV infection. Circulation 2018;137(21):2203–14.

[11] Srinivasa S, Fitch KV, Wong K, et al. RAAS activation is associated with visceral adi-
posity and insulin resistance among HIV-infected patients. J Clin Endocrinol Metab
2015;100(8):2873–82.